NCT06862739 Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
| NCT ID | NCT06862739 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Nabiqasim Industries (Pvt) Ltd |
| Condition | Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 800 participants in total. It began in 2025-10-30 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.
Eligibility Criteria
Inclusion criteria 1. Patients of any gender 2. Patients aged between 18-80 years 3. Patients having HbA1c 8 % or above 4. Patients diagnosed with type II diabetes (more than at least 06 months) 5. Patients already on at least 02 or more anti-diabetic agents 6. Patients not allergic to empagliflozin, linagliptin, or metformin Exclusion criteria 1. Patients with age less than 18 2. Patients with Type-I diabetes 3. Patients having diabetes for less than 06 months 4. Patients on GLP-1 and GIP 5. Patients who are pregnant or lactating females 6. Patients with decompensated chronic liver disease (DCLD) 7. Patients with eGFR less than 30 ml 8. Patients with end-stage heart failure (NYHA Class 4) 9. Patients who are allergic to empagliflozin, linagliptin, or metformin 10. Patients who are not willing to consent 11. Patients who are unable to give medical history
Frequently Asked Questions
Who can join the NCT06862739 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06862739 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06862739 currently recruiting?
Yes, NCT06862739 is actively recruiting participants. Visit ClinicalTrials.gov or contact Nabiqasim Industries (Pvt) Ltd to inquire about joining.
Where is the NCT06862739 trial being conducted?
This trial is being conducted at Faisalabad, Pakistan, Lahore, Pakistan.
Who is sponsoring the NCT06862739 clinical trial?
NCT06862739 is sponsored by Nabiqasim Industries (Pvt) Ltd. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.